DK3229831T3 - Fremgangsmåder og sammensætninger til reduktion af vækst, migration og invasivitet af hjernecancerstamceller og forbedring af overlevelsen for patienter med hjernetumorer - Google Patents

Fremgangsmåder og sammensætninger til reduktion af vækst, migration og invasivitet af hjernecancerstamceller og forbedring af overlevelsen for patienter med hjernetumorer Download PDF

Info

Publication number
DK3229831T3
DK3229831T3 DK15834638.7T DK15834638T DK3229831T3 DK 3229831 T3 DK3229831 T3 DK 3229831T3 DK 15834638 T DK15834638 T DK 15834638T DK 3229831 T3 DK3229831 T3 DK 3229831T3
Authority
DK
Denmark
Prior art keywords
invasiveness
migration
patients
growth
compositions
Prior art date
Application number
DK15834638.7T
Other languages
Danish (da)
English (en)
Inventor
Angelo Luigi Vescovi
Elena Binda
Original Assignee
Hyperstem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyperstem Sa filed Critical Hyperstem Sa
Application granted granted Critical
Publication of DK3229831T3 publication Critical patent/DK3229831T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK15834638.7T 2014-12-10 2015-12-09 Fremgangsmåder og sammensætninger til reduktion af vækst, migration og invasivitet af hjernecancerstamceller og forbedring af overlevelsen for patienter med hjernetumorer DK3229831T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462090029P 2014-12-10 2014-12-10
PCT/IB2015/002577 WO2016092378A1 (en) 2014-12-10 2015-12-09 Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors

Publications (1)

Publication Number Publication Date
DK3229831T3 true DK3229831T3 (da) 2020-06-15

Family

ID=55353245

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15834638.7T DK3229831T3 (da) 2014-12-10 2015-12-09 Fremgangsmåder og sammensætninger til reduktion af vækst, migration og invasivitet af hjernecancerstamceller og forbedring af overlevelsen for patienter med hjernetumorer

Country Status (9)

Country Link
US (2) US10688167B2 (enExample)
EP (1) EP3229831B1 (enExample)
JP (1) JP6921755B2 (enExample)
KR (1) KR102674191B1 (enExample)
AU (1) AU2015359043C1 (enExample)
CA (1) CA2970140A1 (enExample)
DK (1) DK3229831T3 (enExample)
ES (1) ES2796973T3 (enExample)
WO (1) WO2016092378A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10852069B2 (en) 2010-05-04 2020-12-01 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a fractal heat sink
ES2796973T3 (es) * 2014-12-10 2020-11-30 Hyperstem Sa Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales
EP3700546B1 (en) * 2017-10-25 2023-08-16 Wntresearch AB Wnt5a peptides in reduction of cancer stem cells
KR101921836B1 (ko) 2017-11-23 2018-11-26 서울대학교병원 피부성체 줄기세포의 분화 조절 방법, 및 피부성체 줄기세포의 분화 조절용 조성물 및 키트
US20210041443A1 (en) * 2018-04-24 2021-02-11 Universidade Do Minho Wnt6 as glioblastoma oncogenic biomarker, and uses of inhibitors thereof
EP3613757A1 (en) * 2018-08-20 2020-02-26 Wntresearch AB Solution phase routes for wnt hexapeptides
EP3666789A1 (en) * 2018-12-14 2020-06-17 Wntresearch AB Linear solution phase routes for wnt hexapeptides
US12678067B1 (en) 2019-03-20 2026-07-14 Biological Art Group, Inc. Telemetry implants
EP3955950A1 (en) * 2019-04-16 2022-02-23 Wntresearch AB Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer
WO2021034784A1 (en) 2019-08-16 2021-02-25 Poltorak Technologies, LLC Device and method for medical diagnostics
CN114081954B (zh) * 2021-10-30 2023-02-28 中国人民解放军陆军军医大学第一附属医院 用于胶质母细胞瘤治疗的药物组合物以及预后的诊断试剂
CN116173048B (zh) * 2023-01-19 2026-06-16 温州医科大学附属第一医院 棉子糖及其衍生物在胶质母细胞瘤治疗中的应用
WO2025088835A1 (ja) * 2023-10-25 2025-05-01 国立大学法人大阪大学 ヒト化抗ckap4抗体又はその抗原結合性断片

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP1226172A1 (en) 1999-11-05 2002-07-31 Forskarpatent i Syd AB Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
DK2384763T3 (en) 2005-05-30 2015-07-20 Wntres Ab Peptide ligand for disrupting cancer cell migration
RU2517190C2 (ru) * 2008-08-13 2014-05-27 Внтрисерч Аб Применение производных пептида wnt5-a для лечения меланомы и рака желудка
EP2523974A4 (en) * 2010-01-12 2013-11-06 Oncomed Pharm Inc WNT BINDER AND APPLICATIONS THEREOF
EP2446895A1 (en) 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
EP2726880B1 (en) * 2011-07-01 2019-04-17 Wntresearch AB Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients
US20140171356A1 (en) * 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
ES2796973T3 (es) * 2014-12-10 2020-11-30 Hyperstem Sa Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales

Also Published As

Publication number Publication date
HK1245152A1 (en) 2018-08-24
AU2015359043A1 (en) 2017-06-29
CA2970140A1 (en) 2016-06-16
US20200345821A1 (en) 2020-11-05
US10688167B2 (en) 2020-06-23
KR102674191B1 (ko) 2024-06-11
ES2796973T3 (es) 2020-11-30
EP3229831B1 (en) 2020-03-11
AU2015359043B2 (en) 2021-09-02
US20170368158A1 (en) 2017-12-28
US11357840B2 (en) 2022-06-14
KR20170098861A (ko) 2017-08-30
EP3229831A1 (en) 2017-10-18
WO2016092378A1 (en) 2016-06-16
AU2015359043C1 (en) 2022-01-06
NZ732532A (en) 2024-10-25
JP6921755B2 (ja) 2021-08-18
JP2018500390A (ja) 2018-01-11

Similar Documents

Publication Publication Date Title
IL292504B1 (en) -methods of preparing t cells for t cell therapy
IL276907A (en) Modified stem cell memory t cells, methods of making and methods of using same
IL253795A0 (en) Methods for treating cancer using activated t cells
IL254734B1 (en) Modified t cells and methods of making and using the same
IL253162A0 (en) Compositions and methods for treatment and detection of cancers
IL246352B (en) Compositions and methods of preparing airway cells
IL253979A0 (en) Methods, preparations and kits for cancer treatment
DK3277842T3 (da) Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
LT3253865T (lt) Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą
NZ731467A (en) Anti-tim3 antibodies and methods of use
IL325567A (en) Methods of treatment using anti-il-17a/f antibodies
PT3297641T (pt) Métodos de armazenamento de sangue total e respetivas composições
DK3102232T3 (da) Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst
HRP20181105T1 (hr) Novi pripravci, upotreba i postupci za njihovo dobivanje
DK3586821T3 (da) Stamcellestimulerende sammensætninger og metoder
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
PT3204386T (pt) Compostos de aminopurina substituída, suas composições e métodos de tratamento com os mesmos
PT3534743T (pt) Calçado, e método de preparar o mesmo
IL292054A (en) Compositions for treatment of abnormal cell growth
IL286225A (en) Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers
IL250495B (en) Stem cell compositions and methods of producing stem cells for therapeutic applications
DK3154677T3 (da) Amorft mesoporøst alumina med høj konnektivitet og fremgangsmåde til fremstilling deraf
PL3251126T3 (pl) Tarcza naświetlana do produkcji radioizotopów, sposób wytwarzania oraz zastosowanie tarczy naświetlanej
IL289849B1 (en) Means and methods for reducing the tumorigenicity of cancer stem cells
KR101985095B9 (ko) 에티오나마이드를 이용한 줄기세포 증식능 향상 방법